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The analgesic properties of myrrh (Commiphora myrrha) have been known since ancient times and depend on the presence of
bioactive sesquiterpenes with furanodiene skeletons. MyrLiq is a C. myrrha extract with a standardized content of curzerene,
furanoeudesma-1,3-diene, and lindestrene (12.31 ± 0.05 g kg−1, 18.84 ± 0.02 g kg−1, and 6.23 ± 0.01 g kg−1, resp.) and a high total
furanodiene content (40.86 ± 0.78 g kg−1). A balanced sample of 95 female and 89 male volunteers (with ages ranging from 18
to older than 60 years) exhibiting different pain pathologies, including headache, fever-dependent pain, joint pain, muscle aches,
lower back pain, and menstrual cramps, was divided into two groups. The experimental group received 1 capsule/day containing
either 200mg or 400mg of MyrLiq (corresponding to 8mg and 16mg of bioactive furanodienes, resp.) for 20 days, and the placebo
group was given the same number of capsules with no MyrLiq. A score was recorded for all volunteers based on their previous
experience with prescribed analgesics. For themale volunteers, pain alleviation was obtained with 400mg ofMyrLiq/day for almost
all pathologies, whereas, for female volunteers, alleviation of lower back pain and fever-dependent pain was observed with only
200mg of MyrLiq/day. These results indicate that MyrLiq has significant analgesic properties.
1. Introduction
A significant portion of the world population experiences
some type of pain, which is one of the major causes of loss
of quality of life and medical consultations. Analgesics are
among the most prescribed classes of drugs to relieve pain.
In addition to disease- or injury-related pain, hyperalgesia
(enhanced responses to normally painful stimuli) and allo-
dynia (painful responses to normally nonpainful stimuli)
are frequently experienced [1]. The correct use of analgesics
includes oral administration, treatment at regular intervals,
prescription based on pain intensity, individually adapted
dosages, and constant vigilance regarding the necessary
information on when and how to administer the medications
[2]. In addition to synthetic drugs, several plant extracts
are used for their analgesic activity, and approximately 210
plant species belonging to 79 families with activity mediated
by opioidergic receptors have been identified in various
pharmacological studies [3]. Bioactive natural compounds
exerting analgesic activity include alkaloids of opium poppy
(Papaver somniferum) and cannabinoids of hemp (Cannabis
sativa var. indica) [4]. In addition to monoterpenes from
different essential oils [5], other terpenoid classes exhibit
analgesic action. For instance, the sesquiterpene parthenolide
present in feverfew (Tanacetum parthenium) exerts analgesic
activity [6, 7], and the sesquiterpene lactone argolide from
the aerial part of Artemisia glabella exhibits analgesic activity
comparable to that of diclofenac [8]. Furanosesquiterpenes
with analgesic activity, such as furanoelemanes, furanoeudes-
manes, and furanogermacranes, are present in the gum resin
extracts of myrrh [9].
Myrrh is the exudate produced by the bark of plants
belonging to the genus Commiphora (Burseraceae family),
which comprises more than 150 species originating mainly
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from arid tropical and subtropical regions [10, 11]. The so-
called truemyrrh is produced byCommiphoramyrrha (Nees)
Engl., also known as C. molmol Engl. or Balsamodendron
myrrha Nees. This plant has been used as a wound-healing
extract since ancient times, with medicinal uses dating
back to Biblical times [12, 13]. The myrrh furanodienes
curzerene, furanoeudesma-1,3-diene, and lindestrene are
primarily responsible for the myrrh aroma as well as the
analgesic activity of myrrh [14].
MyrLiq is a C. myrrha extract produced by Biosfered S.r.l.
(Italy) and is characterized by a high content of bioactive
furanodienes. Here, we report on the chemical analysis of the
furanodiene content of MyrLiq and its analgesic action based
on a preclinical double-blind controlled study of male and
female volunteers.
2. Materials and Methods
2.1. Reagents. MyrLiq, a myrrh [Commiphora myrrha (Nees)
Engl.] extract, was provided by Biosfered S.r.l. (Turin, Italy) as
a yellowish powder produced from myrrh gum resins with a
total furanodiene content > 40mg/g [15 CMP02-0101-PD01].
The Certificate of Analysis (CoA) of the product is avail-
able on the company’s web site (http://www.biosfered.com).
Sigma-Aldrich (USA) provided the pure standards of trans-
nerolidol, which were used as internal standards and dis-
solved in hexane (Sigma-Aldrich, USA) at a final concentra-
tion of 10mg/mL. Aliquots of the stock solutions were stored
in 1.5-mL HPLC vials at −80∘C until use.The chemical purity
and integrity of the standard compound were assessed prior
to use.
2.2. Identification and Quantification of MyrLiq Furanodienes.
One hundred milligrams of MyrLiq-PWD were extracted in
a glass tube with 5mL of acetone : hexane 1 : 1 (VWR Inter-
national, Radnor, PA, USA) (extraction ratio 1 : 50w/v) and
500 𝜇g of internal standard (trans-nerolidol). The samples
were vigorouslymixed by vortexing, and the powderwas then
extracted in an ultrasonic bath at 30∘C for 30min. At the
end of the extraction, the samples were mixed by vortexing
and centrifuged for 10min at 5,000𝑔. The supernatant of
the solvent was collected in a glass tube. The extraction was
repeated twice, and the solvent aliquots were combined in the
same glass tube.
Prior to analysis, the extracts were loaded into Pasteur
pipettes filled with MgSO4 (Fluka, USA) to filter the samples
and remove any traces of water. The samples were then
analyzed by gas chromatography (GC) coupled to mass
spectrometry [15] for qualitative analysis of the compounds
and by GC coupled to a flame ionization detector (FID) for
quantitative analysis. The GC-MS analyses were performed
using an Agilent Technologies 6890N gas chromatograph
coupled with an Agilent Technologies 5973Amass spectrom-
eter using a Zebron ZB-5MS (Phenomenex, USA) capillary
column (30m length, 250 𝜇m internal diameter, and 0.25 𝜇m
film thickness). The injector temperature was set at 250∘C,
and a constant helium flow (1.0mL min−1) was used as
the mobile phase. The following temperature program was
used: initial temperature 50∘C, followed by a linear thermal
gradient of 3∘C min−1 up to 200∘C and a second gradient of
10∘C min−1 up to 290∘C. The final temperature was held for
3min. The transfer line temperature to the MSD was 280∘C,
and the ionization energy (𝐸𝐼) was set at 70 eV with a full
scan range of 50–300𝑚/𝑧. The compounds were identified
by comparing their mass spectra to the NIST 98 library using
NIST mass spectral search software v2.0.
Quantitative analysis by GC-FID was performed using
the same chromatographic parameters described above with
the same type of column.The detector (FID) temperature was
set at 280∘C.
2.3. Study Population and Inclusion/Exclusion Criteria. To
assess the effects of MyrLiq, we recruited a population of
test volunteers (89 men and 95 women) and an identical
number of placebo volunteers who were involved in studies
performed by Farmacia Antoniana (San Gillio, Italy) under
the supervision of medical doctors. Informed consent was
obtained. The inclusion criteria encompassed any woman or
man between the ages of at least 18 to older than 60 who
was experiencing headache, fever-dependent pain, joint pain,
muscle aches, lower back pain, or menstrual cramps. The
choice of volunteers was completely balanced, and volunteers
with known anatomical abnormalities were excluded from
this study. Nonspecific symptoms included anorexia, fatigue,
reduced mobility, and signs of delirium (e.g., confusion and
deterioration ofmental or functional status). After explaining
the study and obtaining consent, the volunteers were assigned
to either the placebo or experimental randomized groups.
The randomization was concealed.
2.4. MyrLiq Administration and Dosage. The tablets con-
tained either 200mg or 400mg of the product (correspond-
ing to 8mg and 16mg of bioactive furanodienes, resp.),
395mg of microcrystalline cellulose, and either 5mg of
magnesium stearate (for the 200mg capsules) or 195mg of
microcrystalline cellulose and 5mg of magnesium stearate
(for the 400mg capsules). The choice of the two dosages was
established after several trials performed during explorative
galenic studies (unpublished).Theplacebowas indistinguish-
able in color, taste, and appearance and consisted of all of
the elements above except MyrLiq, which was replaced with
rice proteins (the additive in MyrLiq). The experimental
group received 1 tablet containing either 200 or 400mg
of MyrLiq for 20 days, and the placebo group was given
the same number of tablets with no MyrLiq. A score from
0 (representing no effect) to 10 (representing a maximum
analgesic effect of MyrLiq) was recorded for all volunteers
based on their previous experience with prescribed anal-
gesics (see below). The tablets were administered for 20
days, and, during this time, the volunteers were followed
with alternating visits and telephone calls every 2 days. To
avoid contamination, the volunteers were asked not to use
analgesics or any other natural products for the duration of
the study (except the placebo group, in which volunteers were
asked to immediately report any symptoms). If symptoms
were reported, the volunteers were asked to interrupt the
placebo administration and use the analgesics prescribed by
their medical doctors.The attending physicians, the outcome
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Table 1: Furanodiene content of MyrLiq. Data are expressed as the relative area percentage and content (standard deviation).
Compound Furanodiene area percentage Content (g kg−1)
Curzerene 17.93 (0.20) 12.31 (0.05)
Furanoeudesma-1,3-diene 27.44 (0.17) 18.84 (0.02)
Lindestrene 9.08 (0.06) 6.23 (0.01)
Unknown furanodiene (MW = 216) 0.44 (0.01) 0.30 (0.004)
Dihydrolinderalactone 1.91 (0.02) 1.31 (0.02)
Acetoxy-furanodiene (MW = 274) 0.87 (0.05) 0.59 (0.03)
Acetoxy-furanodiene (MW = 232) 1.85 (0.04) 1.27 (0.03)
Total 59.51 (0.43) 40.86 (0.78)
Table 2: Content of furanodienes in the two types of tablets containing either 200 mg or 400mg of MyrLiq.
Compound
Furanodiene content in tablets
containing 200mg of MyrLiq
(mg)
Furanodiene content in tablets
containing 400mg of MyrLiq
(mg)
Curzerene 2.46 4.92
Furanoeudesma-1,3-diene 3.77 7.54
Lindestrene 1.25 2.50
Unknown furanodiene (MW = 216) 0.06 0.12
Dihydrolinderalactone 0.26 0.52
Acetoxy-furanodiene (MW = 274) 0.12 0.24
Acetoxy-furanodiene (MW = 232) 0.25 0.50
Total 8.17 16.34
assessor, and the statistician were all blinded to the group
allocations.
Pathologies included headache, fever-dependent pain,
joint pain, muscle aches, lower back pain, and menstrual
cramps.
The prescribed analgesics were the following: diclofenac
(DI), ketoprofen (KE), ibuprofen (IB), paracetamol (PA),
tramadol (TR), and ketorolac (KT).
2.5. Statistical Analysis. Kolmogorov–Smirnov tests were
used to assess the data distribution. General linear models
(GLMs) were used to assess the independent effects of age
and sex (random factors) or treatments (fixed factor) on
the scores declared by the patients. Nonparametric analysis
of variance with pairwise post hoc comparisons was used
to assess differences in the scores recorded after treatment
with the placebo, 200mg of MyrLiq, and 400mg of MyrLiq.
The boxplots show the median, quartile, maximum, and
minimum score values, and the outliers are identified with
open asterisks. Spearman rank correlations between the dose
(placebo, 200mg of MyrLiq and 400mg of MyrLiq), “score,”
and “success” (score > 5) variables were analyzed. Cluster
analyses were conducted using the Euclidean distances with
the single-linkage method. All statistical analyses were per-
formed using SPSS (v. 22.0, Chicago).
3. Results and Discussion
3.1. Bioactive Constituents of MyrLiq. The chemical composi-
tion ofMyrLiq comprises several furanodienes, including the
bioactive compounds curzerene, furanoeudesma-1,3-diene,
and lindestrene (Table 1). The presence of these three major
furanodienes is typical of the genus [13, 16, 17], and these
compounds are primarily responsible for the analgesic effects
ofmyrrh extracts [14]. GC-FID quantitative analyses revealed
that the total percentage of identified furanodienes was
approximately 60% of the total volatile fraction, whereas
the total furanodiene content was 40.86 g kg−1 (SD = 0.78)
(Table 1). These results are in agreement with the typical
percentage and content of furanodienes in myrrh reported
previously [18, 19].
After the assessment and authentication of the furano-
diene content of MyrLiq, we prepared two types of tablets
containing either 200 or 400mg of MyrLiq, corresponding
to 8.17mg and 16.34mg of total furanodienes, respectively.
Table 2 specifies the content of the individual furanodienes
in both tablet formulations.
The tablets and the corresponding placebo, which did not
contain MyrLiq, were then administered to the volunteers.
3.2. Baseline Characteristics of the Volunteers. The female
and male volunteers were selected based on different pain
categories, including headache, fever-dependent pain, joint
pain, muscle aches, lower back pain, and menstrual cramps.
The volunteers were asked to compare the effects of MyrLiq
with the drug they had been taking for the specific pain
they were experiencing. We asked the volunteers to score
the effects of MyrLiq on a scale between 0 and 10, with 0
indicating no effect and 10 indicating an effect comparable to
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Table 3: Baseline characteristics of the volunteers.
Demographics Experimental group, MyrLiqadministration Placebo group
Number of volunteers 184 184
Number of women (%) 95 (51.6) 95 (51.6)
Number of men (%) 89 (48.4) 89 (48.4)
Median age (range) 38 (19–61) 38 (19–63)
Age range
18–35 21 (W), 9 (M) 21 (W), 9 (M)
36–45 27 (W), 26 (M) 27 (W), 26 (M)
46–60 29 (W), 30 (M) 29 (W), 30 (M)
Over 60 18 (W), 24 (M) 18 (W), 24 (M)
MyrLiq-PWD, 200mg 34 (W), 39 (M) 34 (W), 39 (M)
MyrLiq-PWD, 400mg 61 (W), 50 (M) 61 (W), 50 (M)
Baseline level
Number for headaches 33 (W), 17 (M) 33 (W), 17 (M)
Comparison with KE, IB, PA
Number for fever-dependent pain 12 (W), 19 (M) 12 (W), 19 (M)
Comparison with PA
Number for joint pain 23 (W), 20 (M) 23 (W), 20 (M)
Comparison with DI, KE
Number for muscle aches 14 (W), 22 (M) 14 (W), 22 (M)
Comparison with DI, KE, PA
Number for lower back pain 3 (W), 11 (M) 3 (W), 11 (M)
Comparison with DI, KE, TR, KT
Number for menstrual cramps 10 (W) 10 (W)
Comparison with KE, IB
Number of tablets (days) 1 (20) 1 (20)
Volunteers not completing the study (%) 18 (9.9) 33 (18.2)
Women not completing the study (%) 11 (11.4) 23 (24.1)
Men not completing the study (%) 7 (8.3) 10 (11.8)
Notes. M = men; W = women; DI = diclofenac; KE = ketoprofen; IB = ibuprofen; PA = paracetamol; TR = tramadol; KT = ketorolac.
that of the drug they had been using to treat the pain. Table 3
presents the demographic and baseline characteristics of the
volunteers.
In general, the reasons for dropping out of the study in
the experimental group included relocation (7), feeling better
prior to the end of treatment (8), contrary advice from a
family doctor (2), and a family perception of ineffectiveness of
MyrLiq (1).The reasons for dropping out in the placebo group
included pain (21), contrary advice from a family doctor (3),
and a family perception of ineffectiveness of MyrLiq (9). The
median follow-up time for both groups was 20 days. The
mean tablet intake was 98% (95% CI: 96.5–98.5%) and was
similar between the experimental and placebo groups.
Overall, the scores assigned by the patients were
explained by the administration of the placebo or MyrLiq
(see the results for a single disease), whereas no significant
differences related to sex and age were observed (𝑃 > 0.05 for
each model). We considered values ≥ 5 as a threshold score
for the volunteers. In general, the level of pain experienced
by the volunteers was comparable to the second level of the
World Health Organization analgesic ladder [20].
3.3. Alleviation of Headache. The scores of this group of vol-
unteers were based on comparing the sensations experienced
with the treatments to the sensations experienced with KE,
IB, and PA. In general, a significant difference was observed
between the placebo group and the treatment group (𝐹104,1
= 133.72, 𝑃 < 0.001). Considering the response of different
age groups independent of the concentration of MyrLiq used
(Figure 1(a)), male and female volunteers both consistently
reacted positively to MyrLiq. The Kruskal Wallis (KW)
nonparametric test performed on the three general categories
(placebo, 200mg MyrLiq, and 400mg MyrLiq) independent
of age consistently showed significant differences for both
men (KW = 20.396,𝑁 = 38, 𝑃 < 0.001) and women (KW =
39.102, 𝑁 = 66, 𝑃 < 0.001) (Figure 1(b)). Moreover, the
pairwise comparisons between the two concentrations of
MyrLiq and the placebo (e.g., 200mg versus placebo and
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Figure 1: Effects of MyrLiq on headache reduction in male and female volunteers. (a) shows the effects of the treatments and placebo on the
different age groups independent of the MyrLiq concentration. (b) shows the effects of the two concentrations of MyrLiq (200 and 400mg)
with respect to the placebo (P) independent of age.
400mg versus placebo) were always significant (𝑃 < 0.001)
for both men and women.
These results indicate that MyrLiq significantly reduces
headache pain in both men and women, and the reduction
in headache pain was obtained with the lowest concentration
of MyrLiq (200mg). Several plant extracts have been used
to alleviate headache pain [21], including cannabis [22],
peppermint, and eucalyptus [23, 24]. A recent study of
the clinical effects of a nutraceutical preparation based on
MyrLiq and ginkgo extracts supplemented with Q10, vitamin
B6, and riboflavin over 6 months in patients experiencing
headaches reported a significant reduction in headaches
[25]. Therefore, our data confirm the efficacy of MyrLiq for
headache reduction.
3.4. Alleviation of Fever-Dependent Pain. The scores of this
group of volunteers were based on a comparison of the
sensations experienced with the treatments to the sensations
experienced with PA. In general, significant differences were
observed between the placebo group and the treatment
group (𝐹62,1 = 65.22, 𝑃 < 0.001) for both female and
male volunteers, and these differences were independent of
the concentration of MyrLiq used (Figure 2(a)). The KW
tests, which were independent of age, consistently showed
significant differences for both men (KW = 19.930, 𝑁 = 38,
𝑃 < 0.001) and women (KW = 13.170, 𝑁 = 24, 𝑃 <
0.001) (Figure 2(b)). The pairwise comparisons between the
two MyrLiq concentrations and the placebo were always
significant (𝑃 < 0.001) for both men and women.
Pain caused by fever was already effectively reduced by
200mg of MyrLiq in both the male and female volunteers,
with a marked effect in women (the only group able to reach
a threshold > 5). MyrLiq did not lower the fever (i.e., had no
antipyretic activity). However, it did reduce the side effects
of fever, including headache, general muscular pain, and
dizziness.
3.5. Alleviation of Joint Pain. The scores of this group of vol-
unteers were based on comparing the sensations experienced
with the treatments to the sensations experiencedwithDI and
KE. In general, a significant difference was observed between
the placebo group and the treatment group (𝐹86,1 = 161.58,𝑃 <
0.001) for both the female and male volunteers independent
of the concentration of MyrLiq used (Figure 3(a)). The KW
test consistently showed significant differences for both men
(KW = 26.133, 𝑁 = 40, 𝑃 < 0.001) and women (KW =
29.786,𝑁 = 46, 𝑃 < 0.001) (Figure 3(b)), independent of age.
For men, a significant difference (𝑃 < 0.001) was observed
only when comparing the placebo and 400mg of MyrLiq,
whereas the pairwise comparisons between the two MyrLiq
concentrations and the placebo were always significant (𝑃 <
0.001) for women.
Joint pain is often associated with osteoarthritis [26] and
includes pathologies affecting articular cartilage, subchon-
dral bone, synovium, ligaments, and periarticular muscles
[27]. Notably, MyrLiq was more effective for women than
menwhen used at a dose of 200mg.The latter group reported
significant effects only at a dose 400mg of MyrLiq. There
are accepted and assumed biological differences between
women andmen, including differences in pain thresholds and
analgesic responses to pain medications [15]. Meta-analysis
studies have observed that women report higher pain severity
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Figure 2: Effects of MyrLiq on fever-dependent pain reduction in male and female volunteers. (a) shows the effects of the treatments and
placebo on different age groups independent of the MyrLiq concentration. Outliers are reported as open circles and far outliers (extreme
values) as asterisks. (b) shows the effects of the two MyrLiq concentrations (200 and 400mg) compared with the placebo (P) independent of
age.
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Figure 3: Effects of MyrLiq on joint pain reduction in male and female volunteers. (a) shows the effects of the treatments and placebo on
different age groups independent of the MyrLiq concentration. Outliers are reported as open circles and far outliers (extreme values) as
asterisks. (b) shows the effects of the two MyrLiq concentrations (200 and 400mg) with respect to the placebo (P) independent of age.
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Figure 4: Effects of MyrLiq on the reduction of muscle aches in male and female volunteers. (a) shows the effects of the treatments and
placebo on different age groups independent of the MyrLiq concentration. Outliers are reported as open circles and far outliers (extreme
values) as asterisks. (b) shows the effects of the two MyrLiq concentrations (200 and 400mg) with respect to the placebo (P) independent of
age.
at lower thresholds and have lower tolerance of noxious
stimulation than men [28]. Increasing evidence indicates
that nutraceutical-based combinations of chondroprotective
and/or anti-inflammatory components can effectively reduce
joint pain without measurable side effects. MyrLiq at a
dose of 100mg kg−1 exhibited prominent analgesic activity,
with an inhibition rate of 70.57%, and significantly reduced
joint pain and stiffness in subjects with mild osteoarthritis
[29]. Therefore, our results confirm the analgesic effects of
MyrLiq on joint pain. With regard to other plant extracts,
sesquiterpenes from Aquilaria spp. and extracts from plants
of the genus Celastrus were also found to reduce joint pain
[30, 31].
3.6. Alleviation of Muscle Aches. The scores of this group of
volunteers were based on comparing the sensations expe-
rienced with the treatments to the sensations experienced
with DI, KE, and PA. In general, a significant difference
was observed between the placebo group and the treatment
group (𝐹72,1 = 100.799, 𝑃 < 0.001) for both female and male
volunteers, independent of the concentration of MyrLiq used
(Figure 4(a)). The KW test consistently showed significant
differences in both men (KW = 32.733, 𝑁 = 44, 𝑃 < 0.001)
and women (KW = 11.487,𝑁 = 28, 𝑃 < 0.001) (Figure 4(b)),
independent of age. For both women and men, a significant
difference (𝑃 < 0.001) was only observed when comparing
the placebo and 400mg of MyrLiq.
Muscle aches, along with joint pain, are among the most
prevalent and distressing symptoms, particularly in diseased
populations [32, 33] or after intense physical activity [34].
Our results indicate that this symptom was alleviated when
MyrLiq was used at dose of 400mg. However, the effects
of lower concentrations were not significant. Reports on the
ability of other plants to alleviate muscle aches include a
study describing the effects of the monoterpene camphor
from Cinnamomum camphora [35].
3.7. Alleviation of Lower Back Pain. The scores of this group
of volunteers were based on comparing the sensations expe-
rienced with the treatments to the sensations experienced
with DI, KE, TR, and KT. In general, a significant difference
was observed between the placebo group and the treatment
group (𝐹28,1 = 65.964, 𝑃 < 0.001) for both female and male
volunteers independent of the concentration of MyrLiq used
(Figure 5(a)). The KW test consistently showed significant
differences that were independent of age in men (KW =
15.505, 𝑁 = 22, 𝑃 < 0.001) but not in women (KW = 4.205,
𝑁 = 6, 𝑃 > 0.05) due to a lack of reports (dropouts) for the
200mg dose (Figure 5(b)). However, the differences between
the women receiving 400mg and placebo were significant
(𝑃 = 0.043). In men, a significant difference (𝑃 < 0.001)
was observed when the placebo was comparedwith either the
200mg or 400mg dose of MyrLiq.
Lower back pain (LBP) generally has a favorable outcome,
with significant improvement within 4 weeks [36]. However,
LBP imposes a substantial economic burden on people living
in industrialized societies [37]. A significant reduction of
LBP in men was observed after administration of 200mg
and 400mg of MyrLiq. For female volunteers, we could only
evaluate the positive effects with the 400mg dose of MyrLiq
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Figure 5: Effects of MyrLiq on lower back pain reduction in male and female volunteers. (a) shows the effects of the treatments and placebo
on different age groups independent of the MyrLiq concentration. (b) shows the effects of the two MyrLiq doses (200 and 400mg) with
respect to the placebo (P) independent of age.
because the sample population receiving 200mg was not
sufficient to obtain a statistical comparison with the placebo
treatment due to dropouts. A recent study described the role
of plant extracts in the reduction of LBP, with particular
reference to preparations based onCapsicum frutescens cream
or plaster [37], Harpagophytum procumbens, and Salix alba
extracts [38].
3.8. Alleviation ofMenstrual Cramps. Thescores of this group
of volunteers were based on comparing the sensations experi-
enced with the treatments to the sensations experienced with
KE and IB. In general, a significant difference was observed
between the placebo group and the treatment group (𝐹20,1
= 24.569, 𝑃 < 0.001) in the female volunteers independent
of the concentration of MyrLiq used (Figure 6(a)). The KW
test showed significant differences (KW = 13.840, 𝑁 = 20,
𝑃 < 0.001) (Figure 6(b)) independent of age. The differences
between the placebo and both the 200mg and 400mg doses
of MyrLiq were consistently significant.
Primary dysmenorrhea refers to painful menstrual
cramps without an organic cause. Although severe menstrual
problems are rarely reported, this problem is associated with
increased physical symptoms and depression [39]. MyrLiq
reduced pain frommenstrual cramps, with significant effects
already observable at the 200mg dose of MyrLiq. However,
the score was below the limit threshold (i.e., 5). Other plants
have been shown to reduce menstrual cramps and disorders.
For instance, Mentha × piperita preparations can apparently
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Figure 6: Effects of MyrLiq on the reduction of menstrual cramps
in female volunteers. (a) shows the effects of the treatments and
placebo on different age groups independent of the MyrLiq concen-
tration. (b) shows the effects of the twoMyrLiq concentrations (200
and 400mg) with respect to the placebo (P) independent of age.
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Figure 7: Cluster analysis of the analgesic responses of male
volunteers after the administration of placebo, 200mg of MyrLiq,
and 400mg ofMyrLiq.The cluster analysis was performed using the
single-linkagemethod, and the Euclidean distances are indicated. PL
= placebo.
reduce the severity of primary dysmenorrhea via certain
analgesicmechanisms [40].Phyllanthusmuellerianus extracts
are also traditionally used to treat menstrual disorders [41],
and Wedelia trilobata is effective against menstrual pain and
reproductive problems in women [42].
3.9. Cluster Analysis of the Responses of Men and Women
to MyrLiq. To evaluate the correlations between the two
MyrLiq concentrations and the placebo in both males and
female volunteers, we performed cluster analyses (CA) using
the Euclidean distances and single-linkage method.
In the male volunteers (Figure 7), CA revealed the
presence of two main clusters, the first containing all of
the placebo results and the second including all of the
treatments. In the latter, the responses to fever-dependent
pain after treatment with 200mg of MyrLiq showed low
statistical linkage with the other treatments, whereas a close
statistical linkagewas observed between the responses to joint
pain and muscle ache relief after treatment with 400mg of
MyrLiq. This subcluster was linked to the responses to fever-
dependent pain and headache after treatment with 400mg
of MyrLiq. The results of this analysis revealed that there
was a difference between the placebo and the treatments
and emphasized the higher efficiency of the 400mg dose of
MyrLiq in male volunteers for the treatment of most of the
pathologies studied.
In female volunteers, CA revealed the presence of two
main clusters (Figure 8). In the first cluster, all placebo
results were linked to the responses of the volunteers with
menstrual cramps and muscle aches after administration
of 200mg of MyrLiq. This result confirms the low efficacy
of 200mg of MyrLiq for these pathologies. In the second
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Figure 8: Cluster analysis of the analgesic responses of female
volunteers after the administration of placebo, 200mg of MyrLiq,
and 400mg of MyrLiq. Cluster analysis was performed using the
single-linkage method, and the Euclidean distances are indicated.
PL = placebo.
cluster, a low statistical linkage was observed between the
alleviation of headache and joint pain with respect to the
other treatments after administration of 200mg of MyrLiq.
However, a close statistical linkage was observed between the
responses of the volunteers with headaches, LBP, joint pain,
andmenstrual pain after administration of 400mgofMyrLiq.
The alleviation of LBP and fever-dependent pain showed
a close statistical linkage after administration of 200mg of
MyrLiq. Overall, these results indicate thatMyrLiq is effective
at a dose of 200mg for pathologies such as LBP and fever-
dependent pain, whereas, for the remaining pathologies, the
best results were obtained with the 400mg dose.
4. Conclusions
MyrLiq is a myrrh extract with a high content of bioactive
furanodienes. The results of this study indicate that MyrLiq
has analgesic activities against some of themost prevalent and
distressing pain symptoms, particularly headaches, muscle
aches, joint pain, lower back pain, fever-dependent pain,
and menstrual cramps. A direct comparison with some of
the most frequently used drugs (e.g., diclofenac, ketoprofen,
ibuprofen, paracetamol, tramadol, and ketorolac) revealed
that MyrLiq has similar effects, although it required a longer
course of treatment (20 days). In male volunteers, the
effects were particularly significant at a dose of 400mg of
MyrLiq/day for almost all pathologies, whereas, for female
volunteers, LBP and fever-dependent pain were already
alleviated after treatment with 200mg ofMyrLiq/day. No side
effects were reported by any of the volunteers. Our results
10 BioMed Research International
confirm the analgesic properties of myrrh furanodienes [14,
43, 44] and support their application as a natural remedy
for a wide range of pathologies in which analgesic effects are
required to alleviate pain and improve quality of life.
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